Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420791 | 0.93 | ATR (0.57) | ATRPRKAA2SCN2ASCN10ACCNC | |
| SCHEMBL16420777 | 0.89 | ATR (0.69) | ATRSCN2ASCN10ACCNCCDK8 | |
| SCHEMBL16420775 | 0.88 | ATR (0.67) | ATRCCNCCDK8MEN1KMT2A | |
| SCHEMBL19101115 | 0.87 | ATR (0.66) | ATRCCNCCDK8MEN1KMT2A | |
| SCHEMBL16489089 | 0.87 | ATR (0.72) | ATRPRKAA2SCN2ASCN10ACCNC | |
| SCHEMBL19101135 | 0.87 | ATR (0.61) | ATRPRKAA2CCNCCDK8MEN1 | |
| SCHEMBL16420790 | 0.85 | ATR (0.69) | ATRCCNCCDK8 | |
| SCHEMBL16489060 | 0.85 | ATR (0.69) | ATRMEN1KMT2A | |
| SCHEMBL19101118 | 0.85 | ATR (0.54) | ATRSCN2ASCN10A | |
| SCHEMBL16420769 | 0.84 | ATR (0.71) | ATRPRKAA2SCN2ASCN10ACCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ATR 2406/4885PRKAA2 4246/4885SCN2A 1805/4885 |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKAA2 98/4885SCN2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.